| Actin type | Acetylation                             | Sequence                           | m/z      | targeted<br>[M+2H] <sup>2+</sup> |
|------------|---|------------------------------------|----------|----------------------------------|
| beta       | no                                      | DDDIAALVVDNGSG <b>MC</b> K         | 1795.783 | 898.395                          |
| beta       | <sup>12</sup> C/ <sup>1</sup> H acetate | <b>D</b> DDIAALVVDNGSG <b>MC</b> K | 1837.793 | 919.400                          |
| beta       | <sup>13</sup> C/ <sup>2</sup> H acetate | <b>D</b> DDIAALVVDNGSG <b>M</b> CK | 1742.819 | 921.913                          |
| gamma      | no                                      | EEEIAALVIDNGSGMCK                  | 1851.845 | 926.426                          |
| gamma      | <sup>12</sup> C/ <sup>1</sup> H acetate | EEEIAALVIDNGSGMCK                  | 1893.855 | 947.431                          |
| gamma      | <sup>13</sup> C/ <sup>2</sup> H acetate | <b>E</b> EEIAALVIDNGSG <b>M</b> CK | 1898.881 | 949.944                          |


**Supplementary Table S1:** List of the 6 theoretical peptide sequences that were targeted by mass spectrometry. Meaning of bold amino acids: oxidation of **M** (+15.994 Da), carbamidomethyl of **C** (+57.021 Da), N-term acetylation for **E** or **D** (+42.010 Da for  $^{12}\text{C}_2/^1\text{H}_3$  and +47.037 Da for  $^{13}\text{C}_2/^2\text{H}_3$ ).

| Label | Chromosome | Start       | Stop        | Size     |
|-------|------------|-------------|-------------|----------|
| ROH   | 3          | 45.476.694  | 54.264.197  | 8.788 MB |
| ROH   | 9          | 65.629.772  | 69.824.256  | 4.194 MB |
| ROH   | 5          | 129.486.905 | 132.169.532 | 2.683 MB |
| ROH   | 15         | 42.922.656  | 45.394.057  | 2.471 MB |
| ROH   | 1          | 142.541.502 | 144.931.626 | 2.39 MB  |
| ROH   | 12         | 85.356.224  | 87.722.701  | 2.366 MB |
| ROH   | 5          | 44.442.578  | 46.404.402  | 1.962 MB |


**Supplementary Table S2:** Identity by descent (IBD) regions found in proband 1.2 with SNP Array. Runs of Homozygosity (ROH) are contiguous regions of the genome where the individual is homozygous across all sites.

## **Supplementary Figure 1:**


XIC for precursor ions  $\label{eq:XIC} \text{Targeted N-term peptide: } Ac\text{-}\text{EEEIAALVIDNGSGM}_{ox}C_{cm}K$ 




## XIC for daughter ions from Nat6 deficient cells Targeted N-term peptide: Ac-EEEIAALVIDNGSGM $_{ox}$ C $_{cm}$ K



## MS/MS spectra for $^{12}C_2/^1H_3$ "light" peptide




MS/MS spectra for 13C2/2H3 "heavy" peptide



**Supplementary Figure 1**: Identification and quantification of the N-terminal acetylated peptide from gamma actin by targeted mass spectrometry. A PRM MS/MS method was designed to measure the two acetylated forms (light or heavy) of the processed N-term peptide taking oxidation of Met (M<sub>ox</sub>) and carbamidomethylation of Cys (C<sub>m</sub>) as fixed modifications. *Left upper panel*: XIC of the two precursors ions (light in red m/z= 947.432, heavy in blue m/z= 949.948) for a control and the NAA80 deficient individual. *Right upper panel*: example from a NAA80 deficient individual of the XIC of all daughter ions taken into account for quantification by their area under the curve (AUC). *Lower panel*: MS/MS spectra of the light and heavy +2 precursors ions, the b-ions series shows the incorporation of a heavy acetylated group at the N-term side of the peptide with a mass difference of 5.027 Da from their light counterpart. (-O) denotes neutral loss of H4COS from the side chain of Cys.

## **Supplementary Figure 2.**



Western blot showing NAA80 expression in healthy controls (Ctrl 1, Ctrl 2) and proband 1.2 with and without (SV40-Empty) vectors expressing NAA80 WT cDNA using either a CMV or SV40 promoter.

**Supplementary Table S3:** 

|        | Considerations regarding               | Chromo |          |         | Geno |           |          | PhyloP and       |
|--------|--|--------|----------|---------|------|-----------|----------|------------------|
| Gene   | pathogenicity                          | some   | Start    | Stop    | type | cDNA      | Protein  | <b>PhastCons</b> |
|        | The PRR14L variant is not present in   |        |          |         |      |           |          |                  |
|        | affected proband 1.4. Phenylalanine    |        |          |         |      |           |          |                  |
|        | and Tyrosine have similar properties   |        |          |         |      |           |          |                  |
|        | and this change is thus not expected   |        |          |         |      |           |          |                  |
|        | to impact the protein structure        |        |          |         |      |           |          | PhyloP: 3.958,   |
| PRR14L | significantly.                         | 22     | 32084196 | 3.2E+07 | A/T  | c.6125T>A | p.F2042Y | PhastCons: 1     |
|        | Segregates with affected individuals   |        |          |         |      |           |          |                  |
|        | (proband 1.2 and 1.4). Affected        |        |          |         |      |           |          |                  |
|        | residue is not conserved. Serine and   |        |          |         |      |           |          |                  |
|        | glycine have similar properties and    |        |          |         |      |           |          |                  |
|        | this change is thus not expected to    |        |          |         |      |           |          |                  |
|        | impact the protein structure           |        |          |         |      |           |          |                  |
|        | significantly. The variant is located  |        |          |         |      |           |          |                  |
|        | in a region of low conservation in the |        |          |         |      |           |          |                  |
|        | protein. Serine to glycine has been    |        |          |         |      |           |          | PhyloP: -0.153,  |
| PLXNB1 | observed in other species.             | 3      | 48460754 | 4.8E+07 | C C  | c.2731A>G | p.S911G  | PhastCons: 0.    |
|        | Segregates with affected individuals   |        |          |         |      |           |          | PhyloP: 4.572,   |
| NAA80  | (proband 1.2 and 1.4). Very            | 3      | 50334572 | 5E+07   | G G  | c.323T>C  | p.L108P  | PhastCons: 1     |

|         | conserved residue, amino-acid<br>change predicted to result in altered<br>protein confirmation (loss of<br>proline). |   |           |           |     |          |         |                             |
|---------|--|---|-----------|-----------|-----|----------|---------|-----------------------------|
| HD A CK | The HDAC6 variant is also present in one of the healthy male siblings  | V | 40.662016 | 4.05 : 07 | C . | 2020-0   |         | PhyloP: 1.82,<br>PhastCons: |
| HDAC6   | (proband 1.1).   | X | 48663916  | 4.9E+07   |     | c.383G>C | p.C128S | 0.998                       |

**Supplementary Table S3:** Genetic variants in proband 1.2 found with Whole Exome Sequencing that remain after filtering.

**Supplementary Table S4** 

| Phenotypic Feautre                              | NAA80     | ACTB     | ACTG1    | ACTA1     | ACTA2 | ACTG2 | ACTC1 |
|---|-----------|----------|----------|-----------|-------|-------|-------|
| High-frequency sensorineural hearing impairment | 50        | 0        | 35       | 0         | 0     | 0     | 0     |
| Prominence of the zygomatic bone                | 25        | 1.515152 | 1.282051 | 0         | 0     | 0     | 0     |
| Congenital ptosis                               | 25        | 5.30303  | 8.333333 | 0         | 0     | 0     | 0     |
| High-frequency hearing impairment               | 14.28571  | 0        | 1.848539 | 0         | 0     | 0     | 0     |
| Snoring   | 14.28571  | 0        | 0        | 0         | 0     | 0     | 0     |
| Peg Shaped maxillary lateral incisors           | 11.1111   | 1.31     | 0        | 0         | 0     | 0     | 0     |
| Infantile axial hypotonia                       | 7.69      | 0        | 0        | 0.3042156 | 0     | 0     | 0     |
| Widely-spaced maxillary central incisors        | 7.14      | 0.67     | 0        | 0         | 0     | 0     | 0     |
| Progressive sensorineural hearing impairment    | 2.325581  | 0.422833 | 1.471985 | 0         | 0     | 0     | 0     |
| Brain imaging abnormality                       | 1.5625    | 0.260417 | 0        | 0         | 0     | 0     | 0     |
| Low posterior hairline                          | 1.470588  | 0.039872 | 0        | 0         | 0     | 0     | 0     |
| Prominent metopic ridge                         | 1.25      | 0.113636 | 0        | 0         | 0     | 0     | 0     |
| Sleep Apnea                                     | 1.162791  | 0        | 0        | 0         | 0     | 0     | 0     |
| Tapered finger                                  | 1.07526   | 0.017618 | 0.053419 | 0         | 0     | 0     | 0     |
| Everted lower lip vermilion                     | 1.02      | 0.030921 | 0        | 0         | 0     | 0     | 0     |
| Self-injurious behavior                         | 0.99      | 0        | 0        | 0         | 0     | 0     | 0     |
| Microretrognathia                               | 0.980392  | 0.089127 | 0        | 0         | 0     | 0     | 0     |
| Eclabion  | 0.9259259 | 0.028058 | 0        | 0         | 0     | 0     | 0     |
| Synophrys                                       | 0.892857  | 0.040584 | 0        | 0         | 0     | 0     | 0     |
| Downturned corners of mouth                     | 0.862069  | 0.026123 | 0        | 0         | 0     | 0     | 0     |
| Highly arched eyebrow                           | 0.7462687 | 0.135685 | 0.0333   | 0         | 0     | 0     | 0     |
| Failure to thrive in infancy                    | 0.6493506 | 0.059032 | 0        | 0         | 0     | 0     | 0     |
| Muscular hypotonia of the Trunk                 | 0.5813953 | 0        | 0        | 1.0290698 | 0     | 0     | 0     |

**Supplementary Table S4:** Phenotypic features with their corresponding occurrence ratio in individuals with NAA80 genetic variants or actin mutations (ACTB, ACTG1, ACTA1, ACTA2, ACTG2, ACTC1).